Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial
Authors:
- Veronica V. RezeljVRVeronica V. Rezelj
- Fred PaddenburgFPFred Paddenburg
- Marie Enajite DiegbeMDMarie Enajite Diegbe
- Julius NangosyahJNJulius Nangosyah
- Emil C. ReisingerEREmil C. Reisinger
- Weihong HuWHWeihong Hu
- Carla TruyersCTCarla Truyers
- Gert ScheperGSGert Scheper
- Mathieu Le GarsMGMathieu Le Gars
- Jenny HendriksJHJenny Hendriks
- Frank StruyfFSFrank Struyf
- Macaya DouoguihMDMacaya Douoguih
Open Access
Abstract
Background: This study aimed to support the end-of-shelf life specification (2.5 × 1010 virus particles [vp]) for the standard Ad26.COV2.S dose (5 × 1010 vp). Methods: This randomized, double-blind Phase 3 study evaluated immunogenicity, reactogenicity, and safety of several Ad26.COV2.S dose levels (range 1.25 to 9 × 1010 vp) in 1593 adults between June 2021 and July 2023. Results: Spike-binding antibody responses 28 days post-dose 1 were non-inferior for the 9 × 1010 vp, but not the 2.5 × 1010 vp group when compared with the standard dose. Non-inferiority was demonstrated in terms of spike-binding antibody responses 14 days post-dose 2 for each dose level, including the lowest dose level of 1.25 × 1010 vp, compared to 28 days after one dose and 14 days after two doses of the standard dose. Spike-binding antibody levels correlated well with virus neutralizing titers. There was no impact of pre-existing Ad26.COV2.S neutralizing titers on immunogenicity at any dose level. All dose levels were well tolerated. Conclusions: This study highlights the challenges associated with conducting clinical studies in a rapidly evolving environment and underscores the importance of platform data that can guide initial vaccine specifications such as shelf life during accelerated vaccine development. The present study supports the end-of-shelf life specifications for the approved Ad26.COV2.S dose, and could provide useful information in future vaccine developments using adenovirus vector vaccines.Keywords
Funding Information
- Janssen Vaccines & Prevention B.V.
This publication has 16 references indexed in Scilit:
- Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding studyVaccine, 2024
- Evaluation of ten (10) SARS-CoV-2 rapid serological tests in comparison with WANTAI SARS-CoV-2 ab ELISA in Burkina Faso, West AfricaVirology Journal, 2023
- Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 VaccineThe Journal of Infectious Diseases, 2022
- Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.SNew England Journal of Medicine, 2022
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19New England Journal of Medicine, 2021
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 VaccineNew England Journal of Medicine, 2021
- Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a studyThe Lancet HIV, 2020
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet, 2020
- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trialThe Lancet, 2020
- Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized studyHuman Vaccines & Immunotherapeutics, 2018